S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Ingevity Stock Forecast, Price & News

+0.33 (+0.52%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
4,380 shs
Average Volume
229,810 shs
Market Capitalization
$2.46 billion
P/E Ratio
Dividend Yield
Price Target

Ingevity MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
46.5% Upside
$93.00 Price Target
Short Interest
2.70% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From $5.95 to $6.80 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Basic Materials Sector

90th out of 248 stocks

Chemicals & Allied Products Industry

9th out of 20 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

Ingevity logo

About Ingevity (NYSE:NGVT) Stock

Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment comprises of pavement technologies, industrial specialties, and engineered polymers. It manufactures products derived from crude tall oil and lignin extracted from the kraft pulping process, as well as caprolactone monomers and derivatives derived from cyclohexanone and hydrogen peroxide. This segment's products are used in various applications comprising warm mix paving, pavement preservation, pavement reconstruction and recycling, oil well service additives, oil production, and downstream applications; and adhesives, agrochemical dispersants, lubricants, printing inks, industrial intermediates and oilfield, coatings, resins, elastomers, bioplastics, and medical devices. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.

NGVT Stock News Headlines

StockNews.com Downgrades Ingevity (NYSE:NGVT) to Buy
See More Headlines

Industry, Sector and Symbol

Chemicals & allied products
Previous Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$118.10 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.39 billion
Cash Flow
$8.13 per share
Book Value
$17.15 per share


Free Float
Market Cap
$2.46 billion

Ingevity Frequently Asked Questions

Should I buy or sell Ingevity stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity
or view top-rated stocks.

What is Ingevity's stock price forecast for 2022?

4 brokers have issued 12 month price objectives for Ingevity's shares. Their NGVT stock forecasts range from $81.00 to $112.00. On average, they expect Ingevity's share price to reach $93.00 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts' price targets for Ingevity
or view top-rated stocks among Wall Street analysts.

How has Ingevity's stock price performed in 2022?

Ingevity's stock was trading at $71.70 at the beginning of 2022. Since then, NGVT stock has decreased by 11.5% and is now trading at $63.47.
View the best growth stocks for 2022 here

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Ingevity

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) issued its quarterly earnings results on Wednesday, May, 4th. The company reported $1.62 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.51. The business earned $382.80 million during the quarter, compared to analyst estimates of $341.58 million. Ingevity had a trailing twelve-month return on equity of 32.84% and a net margin of 8.95%. The company's quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.27 EPS.
View Ingevity's earnings history

What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.65 billion, compared to the consensus revenue estimate of $1.54 billion.

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • Mr. John C. Fortson, Pres, CEO & Director (Age 55, Pay $2.35M)
  • Ms. Mary Dean Hall, Exec. VP, CFO & Treasurer (Age 64, Pay $1.03M)
  • Ms. Stacy Lancaster Cozad, Exec. VP, Gen. Counsel & Sec. (Age 51, Pay $1.39M)
  • Mr. Stuart Edward Woodcock Jr., Exec. VP & Pres of Performance Materials (Age 56, Pay $831.57k) (LinkedIn Profile)
  • Mr. Phillip John Platt, Chief Accounting Officer, Corp. Controller & VP of Financial Planning (Age 41)
  • Mr. Daniel Gallagher, VP of Investor Relations
  • John Nypaver, VP of Treasurer & Investor Relations
  • Mr. Richard White, Sr. VP of Performance Chemicals and Pres of Industrial Specialties & Pavement Technologies (Age 59)
  • Mr. Erik Ripple, Chief Growth & Innovation Officer
  • Mr. Steve Hulme, Sr. VP of Performance Chemicals & Pres of Engineered Polymers (Age 53)

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $63.47.

How much money does Ingevity make?

Ingevity (NYSE:NGVT) has a market capitalization of $2.46 billion and generates $1.39 billion in revenue each year. The company earns $118.10 million in net income (profit) each year or $3.28 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,850 workers across the globe.

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for Ingevity is www.ingevity.com. The company can be reached via phone at (844) 643-8489, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.

This page (NYSE:NGVT) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.